Prezista or Darunavir, the newest anti-AIDS drug seems to be effective in patients who have exhausted all modes of treatment in fighting their resistant HIV virus.

Scientists at the 16th International AIDS Conference said 46% of the patients who received Prezista along with background medication suppressed the virus to levels that were hardly detectable following 48 weeks of treatment

The Food and Drug Administration approves Prezista (darunavir), a new drug for adults with HIV who are not responding to treatment with other antiretroviral drugs. Prezista is a new HIV protease inhibitor that the FDA approved for use with a low-dose of ritonavir and other active anti-HIV agents. Ritonavir is a protease inhibitor that slows the breakdown of Prezista in the body, increasing its concentration in the patient's system.

The FDA says in a statement that infection with HIV causes AIDS, which results in more than 15,000 premature deaths each year in the United States and more than 2.8 million deaths each year worldwide